Rotavirus infections and vaccines: Burden of illness and potential impact of vaccination

Pediatric Drugs

Volumn 12, Issue 4, 2010, Pages 235-256

  Grimwood, Keith ^a   Lambert, Stephen B ^a   Milne, Richard J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Children; Cost effectiveness; RIX 4414, therapeutic use; Rotavirus infections, treatment; Rotavirus W179 9 vaccine, therapeutic use; Vaccines, therapeutic use

Indexed keywords

HUMAN STRAIN ROTAVIRUS VACCINE; PENTAVALENT REASSORTANT ROTAVIRUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; CHILDHOOD MORTALITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; SOCIOECONOMICS; VACCINATION; VIRUS IMMUNITY;

ANIMALS; COST OF ILLNESS; HUMANS; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINATION; VIRAL VACCINES;

EID: 77954526124     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11537200-000000000-00000     Document Type: Review

References (199)

1. Parashar UD, Gibson CJ, Bresee JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12 (2): 304-306
2. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9 (5): 565-572
3. Bilcke J, Van Damme P, Van Ranst M, et al. Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis. PLoS ONE 2009; 4 (6): e6060
4. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375 (9730): 1969-1987
5. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among childrenin2004.JInfect Dis 2009;200 Suppl.1:S9-15
6. Widdowson M-A, Steele D, Vojdani J, et al. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009; 200 Suppl. 1: S1-8
7. Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009; 361 (20): 1919-1921
8. Nokes DJ, Abwao J, Pamba A, et al. Incidence and clinical characteristics of group A rotavirus infections among children admitted to hospital in Kilifi, Kenya. PLoS Med 2008; 5 (7): e153
9. Ramani S, Kang G. Burden of disease and molecular epidemiology of group A rotavirus infections in India. Indian J Med Res 2007; 125 (5): 619-632
10. Bahl R, Ray P, Subodh S, et al. Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains. J Infect Dis 2005; 192 Suppl. 1: S114-9
11. Nelson EAS, Bresee JS, Parashar UD, et al. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008; 26 (26): 3192-3196
12. Sanchez-Padilla E, Grais RF, Guerin PJ, et al. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis 2009; 9 (9): 567-576
13. de Oliveira LH, Danovaro-Holliday MC, Matus CR, et al. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008; 7 (3): 345-353
14. de Oliveira LH, Danovaro-Holliday MC, Andrus JK, et al. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis 2009; 200 Suppl. 1: S131-9
15. Lepage P. Rotavirus infection in Europe: time for effective prevention? Pediatr Infect Dis J 2006; 25 (1): S5-6
16. Flores AR, Szilagyi PG, Auinger P, et al. Estimated burden of rotavirusassociated diarrhea in ambulatory settings in the United States. Pediatrics 2010; 125 (2): e191-8
17. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States 1993-2003. J Infect Dis. 2007. 195. 8. 1117-1125.
18. Widdowson M-A, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119 (4): 684-695
19. Mast TC, Walter EB, Bulotsky M, etal. Burden of childhood rotavirus disease on health systemsinthe United States. Pediatr Infect DisJ2010;29(2): e19-25
20. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis 2006; 25 (1): S7-11
21. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 2008; 27 (1): S20-7
22. Rheingans RD, Antil L, Dreibelbis R, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200 Suppl. 1: S16-27
23. Galati JC, Harsley S, Richmond P, et al. The burden of rotavirus-related illness among young children on the Australian health care system. Aust NZ Public Health 2006; 30 (5): 416-421
24. Harris JP, Jit M, Cooper M, et al. Evaluating rotavirus vaccination in England and Wales: Part I, estimating the burden of disease. Vaccine 2007; 25 (20): 3962-3970 (Pubitemid 46616997)
25. Wheeler JG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reporting to national surveillance. BMJ 1999; 318 (7190): 1046-1050
26. Cortes JE, Curns AT, Tate JE, et al. Trends in healthcare utilization for diarrhea and rotavirus disease in privately insured US children <5 years of age 2001-2006. Pediatr Infect Dis J, 2009, 28, 10,874-878.
27. Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe gastroenteritis in children in the United States. Pediatrics 2008; 122 (6): 1235-1243
28. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007; 195 Suppl. 1: S4-16
29. Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123 (3): e393-400
30. Grimwood K, Huang QS, Cohet C, et al. Rotavirus hospitalisation in New Zealand children under 3 years of age. J Paediatr Child Health 2006; 42 (4): 196-203
31. Gutierrez-Gimeno MV, Martin-Moreno JM, Diez-Domingo J, et al. Nosocomial rotavirus gastroenteritis in Spain: a multicenter prospective study. Pediatr Infect Dis J 2010; 29 (1): 23-27
32. Cunliffe NA, Booth JA, Elliot C, et al. Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis 2010; 16 (1): 55-62
33. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis 2006; 25 (1): S12-21
34. Fruhwirth M, Heininger U, Ehlken B, et al. International variation in disease burden of rotavirus gastroenteritis in children with community-and noso-comially acquired infection. Pediatr Infect Dis J 2001; 20 (8): 784-791 (Pubitemid 32758022)
35. Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004; 22 Suppl. 1: S49-54
36. Smith MJ, Clark HF, Lawley D, et al. The clinical and molecular epidemiology of community-and healthcare-acquired rotavirus gastroenteritis. Pediatr Infect Dis J 2008; 27 (1): 54-58
37. Richardson SC, GrimwoodK,Gorrell R,etal. Extended excretionofrotavirus after severe diarrhoea in young children. Lancet 1998; 351 (9119): 1844-1848
38. Barnes GL, Callaghan SL, Kirkwood CD, et al. Excretion of serotype G1 rotavirus strains by asymptomatic staff: a possible source of nosocomial infection. J Pediatr 2003; 142 (6): 722-725
39. Waisbourd-Zinman O, Ben-Ziony S, Solter E, et al. Hospitalizations for nosocomial rotavirus gastroenteritis in a tertiary pediatric center: a 4-year prospective study. Am J Infect Control 2009; 37 (6): 465-469
40. Grimwood K, Lambert SB. Rotavirus vaccines: opportunities and challenges. Hum Vaccines 2009; 5 (2): 57-69
41. Staat MA, Azimi PH, Berke T, et al. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J 2002; 21 (3): 221-227
42. Grimwood K, Carzino R, Barnes GL, et al. Patients with enteric adenovirus gastroenteritis admitted to an Australian pediatric teaching hospital from 1981-1992. J Clin Microbiol 1995; 33 (1): 131-136
43. O'Ryan ML, Lucero Y, Prado V, et al. Symptomatic and asymptomatic rotavirus and norovirus infections during infancy in a Chilean birth cohort. Pediatr Infect Dis J 2009; 28 (10): 879-884
44. Anderson EJ, Weber SG. Rotavirus infections in adults. Lancet Infect Dis 2004; 4 (2): 91-99
45. Sharma R, Hudak ML, Premachandra BR, et al. Clinical manifestations of rotavirus infection in the neonatal intensive care unit. Pediatr Infect Dis J 2002; 21 (12): 1099-1105
46. Estes MK, Kapikian AZ. Rotaviruses. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2007: 1917-1994
47. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 262 (4): 314-319
48. Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet 2001; 358 (9281): 550-555
49. Grimwood K, Coakley JC, Hudson IL, et al. Serum aspartate aminotransferase levels after rotavirus gastroenteritis. J Pediatr 1988; 112 (4): 597-600
50. Kirton A, Busche K, Ross C, et al. Acute necrotizing encephalopathy in Caucasian children: two cases and review of the literature. J Child Neurol 2005; 20 (6): 527-532
51. Ramig RF. Systemic rotavirus infection. Expert Rev Anti Infect Ther 2007; 5 (4): 591-612
52. Blutt SE, Kirkwood CD, Parreno V, et al. Rotavirus antigenaemia and viraemia: a common event? Lancet 2003; 362 (9394): 1445-1449
53. Sugata K, Taniguchi K, Yiu A, et al. Analysis of rotavirus antigenemia and extraintestinal manifestations in children with rotavirus gastroenteritis. Pediatrics 2008; 122 (2): 392-397
54. Ward RL, Bernstein DI, Young EC, et al. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis 1986; 154 (5): 871-880
55. Zahn M, Marshall GS. Clinical and epidemiological aspects of rotavirus infection. Pediatr Ann 2006; 35 (1): 23-28
56. Ansari SA, Springthorpe VS, Sattar SA. Survival and vehicular spread of human rotaviruses: possible relation to seasonality of outbreaks. Rev Infect Dis 1991; 13 (3): 448-461
57. Grimwood K, Abbott GD, Fergusson DM, et al. Spread of rotavirus within families: a community based study. BMJ 1983; 287 (6392): 575-577
58. Gladstone BP, Iturriza-Gomara M,RamaniS,et al. Polymerase chain reaction in the detection of an 'outbreak' of asymptomatic viral infections in a community birth cohort in south India. Epidemiol Infect 2008; 136 (3): 399-405
59. Ramani S, Arumugam R, Gopalarathanim N, et al. Investigation of the environment and of mothers in transmission of rotavirus infections in the neonatal nursery. J Med Virol 2008; 80 (6): 1099-1105
60. Zerr DM, Allpress AL, Heath J, et al. Decreasing hospital-associated rotavirus infection: a multidisciplinary hand hygiene campaign in a children's hospital. Pediatr Infect Dis J 2005; 24 (5): 397-403
61. Bishop RF, Masendycz PJ, Bugg HC, et al. Epidemiological patterns of rotaviruses causing severe gastroenteritis in young children throughout Australia from 1993 to 1996. J Clin Microbiol 001; 39 (3): 1085-1091
62. Levy K, Hubbard AE, Elsenberg JNS. Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis. Int J Epidemiol 2009; 38 (6): 1487-1496
63. Barnes GL, Uren E, Stevens KB, et al. Etiology of acute gastroenteritis in Melbourne, Australia, from April 1980 to March 1993. J Clin Microbiol 1998; 36 (1): 133-138
64. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335 (14): 1022-1028
65. D'Souza RM, Hall G, Becker NG. Climatic factors associated with hospitalizations for rotavirus diarrhoea in children under 5 years of age. Epidemiol Infect 2008; 136 (1): 56-64
66. Perez Schael I, Gonzalez R, Salinas B. Severity and age of rotavirus diarrhea, but not socioeconomic conditions, are associated with rotavirus seasonality in Venezuela. J Med Virol 2009; 81 (3): 562-567
67. Atchison CJ, Tam CC, Lopman BA. Season of birth and risk of rotavirus diarrhea in children aged <5 years. Epidemiol Infect, 2009, 137,7,957-960.
68. Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009; 325 (5938): 290-294
69. Sethi D, Cumberland P, Hudson MJ, et al. A study of infectious intestinal disease in England: risk factors associated with group A rotavirus in children. Epidemiol Infect 2001; 126 (1): 63-70
70. Dennehy PH, Cortese MM, Begue RE, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in US children. Pediatr Infect Dis J 2006; 25 (12): 1123-1131
71. Huppertz H-I, Salman N, Giaquinto C. Risk factors for severe gastroenteritis. Pediatr Infect Dis J 2008; 27 Suppl. 1: S11-9
72. Grimprel E, Rodrigo C, Desselberger U. Rotavirus disease: impact of coinfections. Pediatr Infect Dis J 2008; 27 Suppl. 1: S3-10
73. Grimwood K, Forbes DA. Acute and persistent diarrhea. Pediatr Clin Nth Amer 2009; 56 (6): 1343-1361
74. Schultz R. Rotavirus gastroenteritis in the Northern Territory, 1995-2004. Med J Aust 2006; 185 (7): 354-356
75. Campbell SJ, Nissen MD, Lambert SB. Rotavirus epidemiology in Queensland during the pre-vaccine era. Com Dis Intel 2009; 33 (2): 204-208
76. RuuskaT.Occurrenceofacute diarrheainatopic and nonatopic infants: the role of prolonged breast-feeding. J Pediatr Gastroenterol Nutr 1992; 14 (1): 27-33
77. Cunliffe NA, Bresee JS, Gentsch JR, et al. The expanding diversity of rotaviruses. Lancet 2002; 359 (9307): 640-641
78. HoshinoY,Kapakian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity and vaccine development. J Health Popul Nutr 2000; 18 (1): 5-14
79. Sharma S, Paul VK, Bhan MK, et al. Genomic characterization of nontypeable rotaviruses and detection of a rare G8 strain in Delhi, India. J Clin Microbiol 2009; 47 (12): 3998-4005
80. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implications for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29-56
81. Centers for Disease Control and Prevention (CDC). Rotavirus surveillance: worldwide, 2001-2008. Morb Mortal Wkly Rep 2008, 57,46, 1255-1257
82. Iturriza-Gomara M, Dallman T, Banyai K, et al. Rotavirus surveillance in Europe, 2005-2008: web-enabled reporting and real-time analysis of geno-typing and epidemiological data. J Infect Dis 2009; 200 Suppl. 1: S215-21
83. Kirkwood CD, Boniface K, Bogdanovic-Sakran N, et al. Rotavirus strain surveillance: an Australian perspective of strains causing disease in hospitalised children from 1997-2007. Vaccine 2009; 27 Suppl. 5: F102-7
84. Hasing ME, Trueba G, Baquero MI, et al. Rapid changes in rotaviral genotypes in Ecuador. J Med Virol 2009; 81 (12): 2109-2113
85. Nelson EAS, Widdowson M-A, Kilgore PE, et al. A decade of the Asian Rotavirus Surveillance Network: achievements and future directions. Vaccine 2009; 27 Suppl. 5: F1-3
86. Cunliffe NA, Ngwira BM, DoveW,etal. Serotype G12 rotaviruses, Lilongwe, Malawi. Emerg Infect Dis 2009; 15 (1): 87-90
87. Freeman MM, Kerin T, Hull J, et al. Phylogenetic analysis of novel G12 rotaviruses in the United States: a molecular search for the origin of a new strain. J Med Virol 2009; 81 (4): 736-746
88. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309 (2): 72-76
89. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182 (6): 1602-1609
90. Chiba S, Yokoyahama T, Nakata S, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 328 (8504): 417-421
91. Coulson BS, Grimwood K,Hudson IL,et al. Roleofcoproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992; 30 (7): 1678-1684
92. Richardson SC, Grimwood K, Bishop RF. Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the radioimmunoprecipitation technique. J Clin Microbiol 1993; 31 (2): 377-385
93. Gorrell RJ, Bishop RF. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children. J Med Virol 1999; 57 (2): 204-211
94. Yuan L, Honma S, Kim I, et al. Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4. J Infect Dis 2009; 200 (9): 1443-1451
95. Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 2009; 28 Suppl. 3: S57-9
96. Tate JE, Curns AT, Cortese MM, et al. Burden of acute gastroenteritis hospitalizations and Emergency Department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn RotaShield vaccine. Pediatrics 2009; 123 (3): 744-749
97. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given oral rotavirus vaccine. N Engl J Med 2001; 344 (8): 564-572
98. Simonsen L, Viboud C, Elixhauser A, et al. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005; 192 Suppl. 1: S36-43
99. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluationofrotavirus gastroenteritis in children. Vaccine 2008; 26 (46): 5798-5801
100. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practice (ACIP). Morb Mortal Wkly Rep 2009; 58 (RR-2): 1-25
101. Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005; 192 Suppl. 1: S17-21
102. Kapikian AZ, Hoshino Y. To serotype or not to serotype: that is still the question. J Infect Dis 2007; 195 (5): 611-614
103. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006; 24 (22): 4821-4829
104. Vesikari T, MatsonDO, Dennehy P, etal. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354 (1): 23-33 (Pubitemid 43048948)
105. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent, human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119 (1): 11-18
106. Kim DS, Lee TJ, Kang JH, et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008; 27 (2): 177-178
107. Yen C, Jakob K, Peckham X, et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of RotaTeq® [abstract no. 4314.7]. Pediatric Academic Societies Annual Meeting; 2009 May 2-5; Baltimore (MD)
108. Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccinederived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010; 125 (2): e438-41
109. Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine. Pediatr Infect Dis J 2009; 28 (3): 177-181
110. Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008; 27 (10): 874-880
111. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq®, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009; 28 (2): 345-351
112. Ciarlet M. The pentavalent rotavirus vaccine RotaTeq® [oral presentation]. 8th International Rotavirus Symposium; 2008 Jun 3-4; Istanbul
113. World Health Organization. Rotavirus vaccines: an update. WHO Wkly Record 2009; 84 (51-52): 533-537
114. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144 (2): 184-190
115. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11 Suppl. 2: S29-35
116. Vesikari T, Karvonen A, Ferrante SA, et al. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. Epub 2010 May 3
117. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of thep entavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007; 26 (12): 1099-1104
118. Goveia MG, DiNubile MJ, Dallas MJ, et al. Efficacy of pentavalent humanbovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008; 27 (7): 656-658
119. Smith CK, McNeal MM, Meyer NR, et al. Rotavirus antigen shedding in premature infants following immunization [poster no. 1158]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
120. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200 Suppl. 1: S291-9
121. Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull WHO 1998; 76 (5): 525-537
122. O'Ryan ML, Hermosilla G, Osorio G. Rotavirus vaccines for the developing world. Curr Opin Infect Dis 2009; 22 (5): 483-489
123. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301 (21): 2243-2251
124. Dennehy PH, Goveia MG, Dallas MJ, et al. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007; 11 Suppl. 2: S36-42
125. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008; 121 (6): 1206-1212
126. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010; 29 (1): 1-5
127. Centers for disease Control and Prevention. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. Morb Mortal Wkly Rep 2010; 59 (22): 687-688
128. Denney PH, Bertrand HR, Silas PE, et al. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122 (5): e1062-6
129. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27 (9): 1333-1339
130. Tregnaghi M, Lopez P, De Leon T, et al. Oral human rotavirus vaccine RIX4414 (Rotarix™) co-administered with routine EPI vaccinations including oral polio vaccine (OPV) is highly efficacious in Latin America [abstract no. 19.020]. 13th International Congress on Infectious Diseases; 2008 Jun 19-22; Kuala Lumpur
131. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005; 24 (6): 481-488
132. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live attenuated rotavirus vaccine, in a randomized, double blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005; 192 Suppl. 1: S6-16
133. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22 (21-22): 2836-2842
134. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24 (9): 807-816
135. Ruiz-Palacios GM, Guerrero ML, Bautista-Marquez A, et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics 2007; 120 (2): e253-61
136. Neuzil K, Madhi SA, Cunliffe N, et al. Immunogenicity of human rotavirus vaccine RIX4414 in South African and Malawian infants [abstract]. 6th World Society for Pediatric Infectious Diseases Congress; 2009 Nov 18-22; Buenos Aires
137. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccines 2009; 5 (6): 414-419
138. MoonS-S, Wang Y, Shane AL, etal. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J. Epub 2010 May 3
139. Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis 2009; 48 (2): 222-228
140. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008; 8 (10): 642-649
141. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354 (1): 11-22
142. Linhares AC, Velazquez FR, Perez-Schael I, etal. Efficacy and safetyofanoral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first2yearsoflife inLatinAmerican infants: arandomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371 (9619): 1181-1189
143. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370 (9601): 1757-1763
144. Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double blind, controlled study. Vaccine 2009; 27 (43): 5936-5941
145. Madhi SA, Cunliffe NA, Steele D, et al. Effect of rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362 (4): 289-298
146. Neuzil K, Madhi S, Cunliffe N, et al. RIX4414 is protective against severe RVGE caused by diverse rotavirus serotypes during the first year of life in African infants [abstract]. 27th Annual Meeting of the European Society for Pediatric Infectious Diseases; 2009 Jun 9-13; Brussels
147. Madhi SA, Kirsten M, Bos P, et al. Efficacy of the human rotavirus vaccine RIX4414 against rotavirus G2P[4]/G8P[4] strains in South African infants [oral presentation]. 6th World Society for Pediatric Infectious Diseases Congress; 2009 Nov 18-22; Buenos Aires
148. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for severityofdiarrheal episodes. ScandJInfect Dis 1990;22(3): 259-267
149. Phua KB, Lim FS, Lau YL, et al. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life [abstract]. 27th Annual Meeting of the European Society for Pediatric Infectious Diseases; Jun 9-13; Brussels
150. De Vos B, Han HH, Bouckenooghe A, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr Infect Dis J 2009; 28 (4): 261-266
151. Omenaca F, Sarlangue J, Wysocki J, et al. Immunogenicity of a rotavirus vaccine (RIX4414) in European pre-term infants with different gestational age [abstract]. 27th Annual Meeting of the European Society for Pediatric Infectious Diseases; 2009 Jun 9-13; Brussels
152. Perez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis 2007; 196 (4): 537-540
153. Cheuvart B, Friedland LR, Abu-Elyazeed R, et al. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatr Infect Dis 2009; 28 (3): 225-232
154. United States Food and Drug Administration. Update on Rotarix vaccine [online]. Available from URL: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm205539.htm [Accessed 2010 May 14]
155. World Health Organization. Rotavirus vaccination-WHO does not recommend any changes to use of Rotarix vaccine [media release], 2010.Mar 10 [online]. Available from URL, http://www.who.int/immunization/newsroom/.news-rotavirus- vaccine-use/en/[Accessed 2010 Mar 30]
156. World Health Organization. Rotavirus vaccination-WHO does not recommend any changes to use of Rotarix vaccine [media release] 2010 Mar 10 [online]. Available from URL http://www.who.int/immunization/newsroom/news-rotavirus- vaccine-use/en/[Accessed 2010 Mar 30]
157. European Medicines Agency. European Medicines Agency sees no safety concerns with the Rotarix oral vaccine [media release]. 2010 Mar 26 [online]. Available from URL: http://www.ema.europa.eu/pressoffice/emea.htm
158. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Statement on rotavirus vaccines [media release]. 2010 May 18 [online]. Available from URL: http://www.tga.gov.au/alerts/
159. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124 (2): 465-471
160. Panozzo CA, Tate JE, Payne DC, et al. Reduction in rotavirus after vaccine introduction: United States, 2000-2009. Morb Mortal Wkly Rep 2009; 58 (41): 1146-1149
161. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125 (2): e208-13
162. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201 (11): 1617-1624
163. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125 (2): e199-207
164. Anderson EJ, Rupp A, Shulman ST, et al. Impact of vaccination on nosocomial transmission of rotavirus [poster no. 1149]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
165. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009; 191 (3): 157-160
166. Payne DC, Szilagyi PG, Staat MA, et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009; 28 (11): 948-953
167. Carvalho-Costa FA, Araujo IT, Santos de Assis RM, et al. Rotavirus genotype distribution after vaccine introduction, Rio de Janeiro, Brazil. Emerg Infect Dis 2009; 15 (1): 95-97
168. Nakagomi T, Cuevas LE, Gurgel RG, et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after introduction of rotavirus vaccine. Arch Virol 2008; 153 (3): 591-593
169. Patel MM, de Oliveira LH, Bispo AM, et al. Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis 2008; 14 (5): 863-865
170. Gurgel RG, Bohland AK, Vieira SCF, et al. Incidence of rotavirus and allcause diarrhea in Northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009; 137 (6): 1970-1975
171. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010; 201 (3): 363-369
172. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010; 341: c2825. doi: 10.1136/bmj.c2825
173. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010; 362 (4): 299-305
174. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49 (3): 428-431
175. Snelling TL, Andrews RM, Kirkwood CD, et al. Evaluation of the monovalent human rotavirus vaccine RIX4414 following a G2P[4] outbreak [abstract no. G1-1558b]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
176. Giaquinto C, Van Damme P, Huet F, et al., on behalf of the RSG. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007; 195 Suppl. 1: S36-44
177. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modelling studies. Value Health 2003; 6 (1): 9-17
178. WHO Commission on Macroeconomics and Health. Report on macroeconomics and health: investing in health for economic development 2001 [online]. Available from URL: http://www.stluciauhc.org/res/25PDF [Accessed 2010 Jan]
179. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8 (11): 727-733
180. Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeco-nomics 2009; 27 (4): 281-297
181. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales, part II: the potential cost effectiveness of vaccination. Vaccine 2007; 25 (20): 3971-3979 (Pubitemid 46616994)
182. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25 (52): 8851-8860
183. Martin A, Batty A, Roberts JA, et al. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009; 27 (33): 4520-4528
184. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009; 12 (6): 888-898
185. Curns AT, Coffin F, Glasser JW, et al. Projected impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during, 2006-2015. J Infect Dis 2009; 200 Suppl. 1: S49-56
186. Atherly D, Dreibelbis R, Parashar UD, et al. Rotavirus vaccination: costeffectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200 Suppl. 1: S28-38
187. Milne RJ, Grimwood K. Should rotavirus vaccines be includedin the national immunization program of a small developed country? Exp Rev Pharmaco-economics Res 2009; 9 (5): 401-404
188. World Health Organization. Rotavirus vaccination. WHO Wkly Record 2009; 84 (23): 232-236
189. Vesikari T, Karvonen A, Forrest BD, et al. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006; 25 (2): 118-122
190. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348 (18): 1737-1746
191. Han HH, Suryakiran PV, Debrus S, et al. Importance of early protection by vaccinating with a human rotavirus vaccine RIX4414 [oral presentation]. 6th World Society for Pediatric Infectious Diseases Congress; 2009 Nov 18-22; Buenos Aires
192. Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009; 373 (9674): 1543-1549
193. Naghipour M, Nakagomi T, Nalagomi O. Issues with reducing the rotavirusassociated mortality by vaccination in developing countries. Vaccine 2008; 26 (26): 3236-3241
194. Melliez H, Boelle PY, Baron S, et al. Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: the case of Nigeria. Vaccine 2007; 25 (2): 298-305
195. Grimwood K, Bines JE. Rotavirus vaccines must perform in low-income countries too. Lancet 2007; 370 (9601): 1739-1740
196. Patel MM, Clark AD, Glass RI, et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 2009; 27 (22): 2916-2922
197. Grimwood K, Kirkwood CD. Human rotavirus vaccines: too early for the strain to tell. Lancet 2008; 371 (9619): 1144-1145
198. Munos MK, Fischer Walker CL, Black RE. The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol 2010; 39 (2): i56-62
199. Wardlaw T, Salama P, Brocklehurst C, et al. Diarrhoea: why children are still dying and what can be done. Lancet 2010; 375 (9718): 870-872